Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Patients taking Novo Nordisk’s anti-obesity jab sustained weight loss for up to four years and had a ...
Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...
Novo Nordisk, the pharmaceutical company behind Ozempic, has launched a national campaign promoting its injectable ...
Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.
LONDON - Patients taking Novo Nordisk’s Wegovy obesity treatment maintained an average of 10 per cent weight loss after four years, potentially boosting the drugmaker’s case to insurers and ...
LONDON, May 14 (Reuters) - Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, potentially boosting the drugmaker's case to insurers ...
Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are ...
FAT jabs could be the cancer hope of the future after early studies found they reduce the risk of tumours. The world’s top ...
Benzinga - by Vandana Singh, Benzinga Editor. Researchers highlighted on Monday that certain genes may help identify patients with obesity who are most likely to respond strongly to Novo Nordisk A/S’s ...